Heweneural 1% (Lidocaine Hydrochloride Monohydrate)

Heweneural 1% is indicated for local anesthesia and dermal infiltration in a variety of minor procedures. The solution provides rapid onset of numbness lasting sufficient time for the procedure.

• Intradermal anesthesia for minor surgical excisions, biopsies, or suturing.
• Diagnostic skin testing or minor dermatologic interventions requiring temporary numbness.
• Pain control during superficial wound debridement or burn dressing changes.
• Dermal infiltration for postoperative analgesia after minor outpatient procedures.
• Adjunctive anesthesia for catheter placement or needle aspiration in superficial tissues.

• Lidocaine hydrochloride monohydrate acts by reversibly binding to the intracellular portion of voltage‑gated sodium channels in neuronal membranes. This binding stabilizes the channel in its inactive state, preventing the influx of sodium ions during depolarization. As a result, the generation and propagation of action potentials along peripheral nerves are inhibited, producing a localized loss of sensation without affecting surrounding tissues.

Adverse reactions to intradermal lidocaine are generally dose‑related and may range from mild to severe.

Common

• Transient burning or stinging sensation at the injection site that usually resolves within minutes.
• Mild erythema, localized swelling, or bruising around the puncture area.
• Prolonged numbness that extends beyond the expected duration of the procedure.

Serious

• Allergic reactions such as urticaria, angioedema, or anaphylaxis requiring immediate medical attention.
• Cardiovascular disturbances including hypotension, bradycardia, tachyarrhythmias, or cardiac arrest in rare cases.
• Central nervous system toxicity manifesting as seizures, tremor, confusion, or loss of consciousness.

Before using Heweneural 1%, clinicians should assess patient history and follow safety guidelines to minimize risk.

• Verify absence of known hypersensitivity to amide‑type local anesthetics or lidocaine.
• Use the lowest effective dose and limit total administered volume per session.
• Avoid intravascular injection; aspirate before depositing the solution intradermally.
• Exercise caution in patients with cardiac conduction disorders, severe liver disease, or heart failure.
• Consider alternative anesthesia for pregnant or breastfeeding women, as safety data are limited.
• Monitor patients for signs of systemic toxicity, especially when large areas are treated.
• Store the product at controlled room temperature, protected from light, and discard after the expiration date.

Lidocaine may interact with other agents that affect cardiac conduction or metabolism, and certain combinations require special attention.

Avoid

• Concurrent use of Class I antiarrhythmic drugs (e.g., quinidine, procainamide) that can potentiate cardiotoxicity.
• Co‑administration with other local anesthetics, which may increase total systemic exposure.
• Use with potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) that could reduce lidocaine clearance.

Use with caution

• Beta‑blockers or calcium channel blockers, which may enhance lidocaine’s negative inotropic effects.
• General anesthetics such as propofol or volatile agents that can synergize CNS depression.
• Epinephrine‑containing solutions, as vasoconstriction may alter lidocaine absorption rates.